SCHEMBL2175359

SCHEMBL2175359

COc1ccc2c(Oc3ccc(C(OC(=O)CC(O)(CC(=O)O)C(=O)O)C(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 17/20 0.59
CSF1R P07333 17/20 0.59
KDR P35968 15/20 0.59
MET P08581 4/20 0.59
PDGFRA P16234 1/20 0.59
FLT3 P36888 6/20 0.49
IGF1R P08069 2/20 0.42
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38
RPS6KA5 O75582 1/20 0.38
ABL1 P00519 1/20 0.38
INSR P06213 1/20 0.38
LCK P06239 1/20 0.38
FES P07332 1/20 0.38
LYN P07948 1/20 0.38
RET P07949 1/20 0.38
FGR P09769 1/20 0.38
KIT P10721 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175412 0.84 PDGFRB (0.65) PDGFRBCSF1RKDRMETPDGFRA
Citric Acid SCHEMBL2175347 0.84 PDGFRB (0.84) PDGFRBCSF1RKDRMETPDGFRA
SCHEMBL2173849 0.82 PDGFRB (0.66) PDGFRBCSF1RKDRMETPDGFRA
Citric Acid SCHEMBL4709373 0.82 CSF1R (0.52) PDGFRBCSF1RKDRMETPDGFRA
SCHEMBL2176059 0.80 KDR (0.61) PDGFRBCSF1RKDRMETPDGFRA
SCHEMBL2174355 0.79 PDGFRB (0.61) PDGFRBCSF1RKDRMETPDGFRA
SCHEMBL2176080 0.75 PDGFRB (1.00) PDGFRBCSF1RKDRMETPDGFRA
SCHEMBL2173846 0.74 PDGFRB (0.94) PDGFRBCSF1RKDRMETPDGFRA
Fumaric Acid SCHEMBL2175416 0.73 PDGFRB (0.91) PDGFRBCSF1RKDRMETPDGFRA
Maleic Acid SCHEMBL2175406 0.73 PDGFRB (0.91) PDGFRBCSF1RKDRMETPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 PDGFRB 2155/4885CSF1R 818/4885KDR 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.